Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06305702

Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer

HER2-positive Metastatic Breast Cancer Clinical Trial

Official title:
Multicenter Real-world Clinical Study of Inetetamab-based Therapy in HER2-positive Metastatic Breast Cancer

Clinical Trial Summary

A multicenter real-world study was conducted to gather clinicopathological data from patients with HER2-positive metastatic breast cancer who were treated with inetetamab between 2022 and 2023. The study aimed to estimate the progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs) associated with inetetamab therapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06305702
Study type Observational
Source Liaoning Tumor Hospital & Institute
Contact
Status Completed
Phase
Start date July 1, 2022
Completion date January 31, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06278870 - Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial Phase 3
Recruiting NCT04692831 - Testing a New Imaging Agent to Identify Cancer Phase 1
Recruiting NCT04385563 - A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC. Phase 3
Terminated NCT04778982 - Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer
Active, not recruiting NCT03417544 - Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC Phase 2
Recruiting NCT04319757 - ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors Phase 1
Recruiting NCT05188495 - Trastuzumab(Henlius®) Combined With Pertuzumab(Perjeta®) and Chemotherapy in Chinese Patients With Her2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab
Recruiting NCT05583110 - Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer Phase 2
Recruiting NCT06298084 - Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd Phase 1/Phase 2
Recruiting NCT05650879 - ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03979339 - Feasibility of a New Technology for Isolating Circulating Tumour Cells N/A
Recruiting NCT05042791 - A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases Phase 2
Active, not recruiting NCT05555251 - BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors Phase 1/Phase 2
Withdrawn NCT04602117 - ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer Phase 1
Recruiting NCT05959291 - Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer N/A
Recruiting NCT06299852 - Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer N/A
Completed NCT02605915 - Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer Phase 1
Recruiting NCT05868226 - PRE-I-SPY Phase I/Ib Oncology Platform Program Phase 1
Recruiting NCT05800275 - Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease Phase 2
Recruiting NCT05036252 - Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity